-
-
-
-
-
-
-
Benchmark Reiterates Hold Rating on RXO, Inc. (RXO) Following Jury Verdict in Lipe v. Lupus Superior
-
-
-
-
-
-
-
Stifel Upgrades RXO, Inc. (RXO) to Buy
-
-
-
-
-
-
-
RXO, Inc. (RXO) PT Lowered to $15 at BofA Securities
-
-
-
-
-
-
-
Raymond James Reiterates Market Perform Rating on RXO, Inc. (RXO)
-
-
-
-
-
-
-
Wolfe Research Upgrades RXO, Inc. (RXO) to Peerperform
-
-
-
-
-
-
-
RXO, Inc. (RXO) PT Raised to $18 at BofA Securities
-
-
-
-
-
-
-
Truist Sees RXO, Inc. (RXO) as 'A Well-Positioned, Underappreciated Story'
-
458,215 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

